Sichuan Biokin Pharmaceutical Co., Ltd.: all 149 studies

Page 2 of 2. Open to participants first (104), then studies with results posted, then the rest; newest registration first within each.

• A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid TumorsRecruitingNCT05461768Phase 1
• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid TumorRecruitingNCT05262491Phase 1
• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid TumorRecruitingNCT05194982Phase 1
• A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid TumorsRecruitingNCT04794972Phase 1
• Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid TumorsActive, not recruitingNCT07021066Phase 1
• A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)Active, not recruitingNCT06857175Phase 3
• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic ChordomaActive, not recruitingNCT06787664Phase 2
• Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsTerminatedNCT06714617Phase 1
• Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1TerminatedNCT06714591Phase 1
• A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06668961Phase 2
• A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)Active, not recruitingNCT06500026Phase 3
• A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT06498986Phase 2
• A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerActive, not recruitingNCT06445400Phase 2
• A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06423885Phase 2
• A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)Active, not recruitingNCT06382142Phase 3
• A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)Active, not recruitingNCT06382129Phase 3
• A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)Active, not recruitingNCT06382116Phase 3
• A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)Active, not recruitingNCT06343948Phase 3
• A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerActive, not recruitingNCT06316531Phase 3
• A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)Active, not recruitingNCT06304974Phase 3
• A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)Active, not recruitingNCT06118333Phase 3
• A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06114511Phase 1/2
• A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid TumorsActive, not recruitingNCT05949619Phase 1/2
• A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05949606Phase 1/2
• A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological MalignanciesActive, not recruitingNCT05944978Phase 1/2
• A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell CarcinomaActive, not recruitingNCT05943795Phase 3
• A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05880706Phase 2
• A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05668858Phase 1/2
• A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHLActive, not recruitingNCT05627856Phase 1/2
• A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)Active, not recruitingNCT05485753Phase 1/2
• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid TumorsActive, not recruitingNCT05393427Phase 1
• A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid TumorsActive, not recruitingNCT05385692Phase 1
• A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid TumorsActive, not recruitingNCT05339685Phase 1
• A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT05192486Phase 1/2
• A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT05160545Phase 1
• A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic MalignancyActive, not recruitingNCT05104775Phase 1
• A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCActive, not recruitingNCT05054439Phase 2
• A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCCActive, not recruitingNCT05044897Phase 2
• SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System MalignanciesTerminatedNCT05039944Phase 2
• A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid TumorsWithdrawnNCT05039931Phase 1
• SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.Active, not recruitingNCT05022654Phase 2
• SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.Active, not recruitingNCT05020769Phase 2/3
• SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.Active, not recruitingNCT05020457Phase 2
• A Study of SI-F019 in Healthy ParticipantsCompletedNCT04851444Phase 1
• A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsActive, not recruitingNCT04606472Phase 1
• Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaActive, not recruitingNCT04606433Phase 1
• A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial TumorsActive, not recruitingNCT04603287Phase 1
• Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.Status unknownNCT03855826Phase 4
• Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) InjectionStatus unknownNCT03853369

← Sichuan Biokin Pharmaceutical Co., Ltd. overview and focus areas